Quarterly report pursuant to Section 13 or 15(d)

Business (Details Narrative)

v3.21.2
Business (Details Narrative) - USD ($)
1 Months Ended
Mar. 02, 2021
Nov. 30, 2020
Nov. 18, 2020
Jan. 18, 2021
Sep. 30, 2021
Dec. 31, 2020
Cash and cash equivalents         $ 5,960,594 $ 5,069,266
Proceeds from issuance of common stock and warrants   $ 4,591,349        
Estimated gross proceeds from offering of shares $ 502,717          
Common Stock [Member]            
Estimated gross proceeds from offering of shares $ 3,689,761          
Reverse stock split     1-for-6 reverse split      
Phase 1b Clinical Trial [Member] | Minimum [Member]            
Estimated cost of clinical trial       $ 2,500,000    
Phase 1b Clinical Trial [Member] | Maximum [Member]            
Estimated cost of clinical trial       $ 2,900,000